Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 2
2008 3
2009 4
2010 4
2011 2
2012 8
2013 5
2014 5
2015 12
2016 8
2017 3
2018 12
2019 17
2020 19
2021 24
2022 22
2023 18
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Results by year

Filters applied: . Clear all
Page 1
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Provenzano M, Puchades MJ, Garofalo C, Jongs N, D'Marco L, Andreucci M, De Nicola L, Gorriz JL, Heerspink HJL; ROTATE-3 study group; ROTATE-3 study group members. Provenzano M, et al. J Am Soc Nephrol. 2022 Aug;33(8):1569-1580. doi: 10.1681/ASN.2022020207. Epub 2022 Apr 19. J Am Soc Nephrol. 2022. PMID: 35440501 Free PMC article. Clinical Trial.
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.
Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Fontán F, Del Vecchio L, Floege J, Goicoechea M, Haaland B, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Wetzels JFM, Woodward M, Heerspink HJL; CKD-EPI Clinical Trials Consortium. Inker LA, et al. Nat Med. 2023 Jul;29(7):1867-1876. doi: 10.1038/s41591-023-02418-0. Epub 2023 Jun 17. Nat Med. 2023. PMID: 37330614
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.
Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration. Coresh J, et al. Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8. Lancet Diabetes Endocrinol. 2019. PMID: 30635225 Free PMC article.
Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD.
Heerspink HJL, Inker LA, Tighiouart H, Collier WH, Haaland B, Luo J, Appel GB, Chan TM, Estacio RO, Fervenza F, Floege J, Imai E, Jafar TH, Lewis JB, Kam-Tao Li P, Locatelli F, Maes BD, Perna A, Perrone RD, Praga M, Schena FP, Wanner C, Xie D, Greene T; on behalf of CKD-EPI CT. Heerspink HJL, et al. Among authors: xie d. J Am Soc Nephrol. 2023 Jun 1;34(6):955-968. doi: 10.1681/ASN.0000000000000117. Epub 2023 Mar 15. J Am Soc Nephrol. 2023. PMID: 36918388 Clinical Trial.
Vam6 reduces iNKT cell function in tumor via modulating AMPK/mTOR pathways.
Bai S, Wu Q, Zhu S, Zhang Y, Chen X, Su M, Pan J, Li S, Yue T, Xu L, Xie D, Tian C, Zhao D, Li X, Hou J, Wang L, Fu S, Xue Y, Jiang A, Li D, Xu T, Tian Z, Zhou R, Zhang H, Bai L. Bai S, et al. Among authors: xie d. Front Immunol. 2023 Jan 19;13:1051045. doi: 10.3389/fimmu.2022.1051045. eCollection 2022. Front Immunol. 2023. PMID: 36741382 Free PMC article.
158 results